|drug2017||Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops) Wiki||1.00|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCoV infection. Natural killer (NK) cells are innate lymphocytes that may serve as useful effectors against danger infection. The purpose of this clinical investigation is to evaluate the safety and efficiency of NK Cells in combination with standard therapy for pneumonia patients infected with 2019-nCoV.
Description: Evaluation of pneumonia improvementMeasure: Improvement of clinical symptoms including duration of fever Time: Measured from day 0 through day 28
Description: Evaluation of pneumonia improvementMeasure: Improvement of clinical symptoms including respiratory frequency Time: Measured from day 0 through day 28
Description: Safety evaluationMeasure: Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0 Time: Measured from day 0 through day 28
Description: Marker for 2019-nCoVMeasure: Time of virus nucleic acid test negative Time: Measured from day 0 through day 28
Description: Marker of immunological functionMeasure: CD4+ and CD8+ T cell count Time: Measured from day 0 through day 28
Description: Marker for efficacy of treatmentMeasure: Rate of mortality within 28-days Time: Day 28
Description: Recovery of lung injuryMeasure: Size of lesion area by thoracic imaging Time: Measured from day 0 through day 28
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports